$5 Off with online purchase (regular $39.99)
Take 1 to 3 capsules per day with unchilled water,
or dissolve in mouth, 20-60 minutes after eating, or use as directed by your qualified health consultant. You may also
open the capsule and pour contents over food or use in
recipes that require live yeast for fermentation.
Jarrow Formulas® Saccharomyces Boulardii +MOS contains live, friendly yeast and MOS (MannanOligoSaccharide) derived from S. cerevisiae. MOS are oligosaccharides consisting
of multiple mannose units. MOS directly block bacterial
attachment to the epithelial cells of the intestine and reduce
their proliferation.
The combination of Saccharomyces boulardii and MOS
provides enhanced support to the intestinal tract and assists
gut immune response against undesirable bacterial.
Keep out of the reach of children.
SUPPLEMENT FACTS Serving Size 1 Tablet
|
Amount |
% DV |
|
|
Saccharomyces Boulardii
(a Subspecies of S. cervisiae)
1.5 Billion Live Cells at time of manufacture |
1.5 Billion Organisms |
* |
|
|
Bio-MOS®
[derived from S. cerevisiae, source of MOS (MannanOligoSaccharide)]
|
200 mg |
* |
* Daily Value not established. |
Other Ingredients: Maltodextrin, magnesium stearate, and ascorbic acid. Capsule consists of gelatin. Contains NO common allergen. Keep refrigerated or in freezer.
Bio-MOS® is a trademark of Alltech.
Yeasts are actually normal inhabitants of the human intestinal tract. Saccharomyces boulardii is a friendly, non-pathogenic yeast. S. boulardii is a unique yeast that produces lactase and acidifies its environment. (Most yeasts require an alkaline environment.) Supplementing with S. boulardii helps maintain a balance of friendly organisms in the intestines.
Microbiologist Edouard Brochu, Ph. D., Institute Rosell, studied S.boulardii and found that it is able to ferment the carbohydrates glucose, fructose, arbutine, maltose, saccharose, raffinose and mannose. These carbohydrates are metabolized by Saccharomyces boulardii into lactic acid and other beneficial acids. Dr. Brochu identifies S. boulardii as a subspecies of the S. cerevasiae, a non-pathogenic yeast. Dr. Brochu’s lab testing has determined that S. boulardii is compatible with acidophilus-type organisms in the intestines (lactobacilli, group D streptococci, and bifidobacterium), so these species do not inhibit each other.
Unhealthful types of yeasts decrease the acidity of the mucosal tissue environment, making these tissues susceptible to pathogens. By acidifying its environment, S. boulardii strengthens the health of mucosal tissue. [NOTE: S. boulardii is NOT related in any way to Candida albicans, a pathogenic yeast of a different genus and species.]
S. boulardii has been studied in humans and is frequently used to treat diarrhea caused by antibiotics. Many of the studies have been published in American medical journals. JA Machado Caetano et al (1986) fed one gram of S. boulardii per day to 96 healthy humans for 7 days. Blood and saliva samples showed increases in various classes of white cells, complement, and the reticuloendothelial system, indicating that the organism is protective to intestinal mucosa along with acidophilus-type organisms.
An interesting study was reported at the 1990 Sixth International AIDS Conference in San Francisco, by Saint Marc et al. In an abstract entitled “Treatment of chronic diarrhea with Saccharomyces boulardii”, 30 AIDS patients with severe, chronic diarrhea (4-8 liters of watery stool per day for the last three months) who had already received four different anti-diarrhea medications without success were studied. Patients received 3 grams per day of Saccharomyces boulardii to restore normal bowel yeast flora. During the feeding of S. boulardii, the subject’s fecal output decreased to less than one per day after 48 hours of treatment, and 8 days after onset [feeding of Saccharomyces boulardii], stools were fully formed.
References
i. Periti P, Tonelli F. “Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.” Chemother 2001 Oct; 13(5): 473-93.
ii. Guslandi M, Mezzi G, Sorghi M, Testoni PA. “Saccharomyces boulardii in maintenance treatment of Crohn's disease.” Dig Dis Sci 2000 Jul; 45(7): 1462-4.
iii. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL. “Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo.”
Am J Gastroenterol 1995 Mar; 90(3): 439-48.
iv. Blehaut H, Massot J, Elmer GW, Levy RH. “Disposition kinetics of Saccharomyces boulardii in man and rat.” Biopharm Drug Disposition. 1989. 10; 353-364.
v. Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R. “Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii.” Ped Res. 1986. 20(2); 192-96.
vi. Buts JP, Bernasconi P, Vaerman JP, Dive C. “Stimulation of secretory component of immunoglobulins in small intestine of rats treated with saccharomyces boulardii. Digestive Dis Sci. Feb 1990. 35(2); 251-56.
vii. Cano N, et al. “Sacchoromyces boulardii: un traitement des colites pseudomembraneuses?” La Presse Medicale. July 1-12, 1989. 18 (26); 1299.